

Intersect ENT Announces Executive Team Appointments

Christine Kowalski Joins as Chief Operations Officer; Susan Stimson Named Chief Strategy Officer

MENLO PARK, Calif.—October 29, 2018 — Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced two new executive team appointments.

Christine Kowalski has joined as Chief Operations Officer. In this role, Kowalski will lead manufacturing, supply chain, quality, facilities and information technology for the company. Kowalski joins Intersect ENT with more than thirty years of experience in the medical device industry, including nearly two decades in operations and supply chain executive leadership. Following 18 years at Guidant/Boston Scientific, Christine held senior executive leadership roles overseeing operations and supply chains for several medical device companies, including ev3 (acquired by Covidien/Medtronic), American Medical Systems/Endo Healthcare Solutions (acquired by Boston Scientific), and RTI Surgical, and most recently served as Vice President of Supply Chain Strategy at Johnson & Johnson. Kowalski earned a bachelor's degree from the University of North Dakota and a master's in management from Purdue University.

Additionally, Intersect ENT executive **Susan Stimson** has assumed the newly created role of Chief Strategy Officer, leading the company's market access, reimbursement and business development efforts. A member of the founding team of Intersect ENT, Stimson most recently served as General Manager of SINUVA, leading the company's transition into a hybrid device and pharmaceutical business. Previously, she ran the marketing and customer service teams.

"We are fortunate to have a world-class team of passionate, skilled leaders in place as we embark on Intersect ENT's next chapter of growth," said Lisa Earnhardt, president and CEO of Intersect ENT.

"Christine is a talented executive with extraordinary experience in scaling complex medical technology operations, and we are thrilled to welcome her to the Intersect ENT family.

"I would also like to congratulate Susan on her new role, in which she will oversee initiatives that are critical to the growth and success of the company. Susan has been instrumental to our success over the last decade."

As previously disclosed, **Rich Kaufman** will retire as the company's Chief Operating Officer in early 2019 and will work in partnership with Kowalski during the transition. Kaufman has assumed the role of Technical Advisor.

All three executives will report to Earnhardt.

About Intersect ENT

Intersect ENT is dedicated to transforming ear, nose and throat care by providing innovative, clinically meaningful therapies to physicians and patients. The company's steroid releasing implants are designed to provide mechanical spacing and deliver targeted therapy to the site of disease. In addition, Intersect ENT is continuing to expand its portfolio of products based on the company's unique localized steroid

releasing technology and is committed to broadening patient access to less invasive and more cost-effective care.

For additional information on the company or the products including risks and benefits please visit www.IntersectENT.com. For more information about SINUVA, please visit www.SINUVA.com.

Intersect ENT®, PROPEL® and SINUVA® are registered trademarks of Intersect ENT, Inc.

###

XENT-G

Intersect ENT, Inc.

Jeri Hilleman, 650-641-2105

ir@intersectENT.com